White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis
Oliver T. Wiebenga(Universidade Federal do Rio de Janeiro), Jeroen J.G. Geurts(Amsterdam Neuroscience), Petra J. W. Pouwels(Amsterdam UMC Location University of Amsterdam), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Martijn D. Steenwijk(Amsterdam University Medical Centers), Menno M. Schoonheim(Amsterdam Neuroscience), Chris H. Polman(Vrije Universiteit Amsterdam), Eva Strijbis(Amsterdam Neuroscience), G.J.A. Nagtegaal(MACOM (United States)), Hanneke E. Hulst(Leiden University)
Cited by 12
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k